24 Results for "

CAR-T cell

" in MedChemExpress (MCE) Product Catalog:
Products (24)

24 Results for "CAR-T cell" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-108691
CAS No.: 1407966-77-1
Purity:  99.48%
Target:  

Itk Btk CXCR PD-1/PD-L1 LAG-3

Research Areas:  

Cancer

PF-06465469 is a covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-144987
CAS No.: 2597933-17-8
Purity:  98.84%
Target:  

CD38 LAG-3 Tim3 PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD + to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-155978A
Purity:  99.80%
RDN2150 TFA is a ZAP-70 inhibitor with an IC50 of 14.6 nM, and it exhibits selectivity for Syk over other kinases. RDN2150 TFA inhibits signal transduction and activation of T cells/CAR-T cells, reduces the phosphorylation level of Erk1/2, suppresses the induction of CD69 and IL-2, and downregulates phosphotyrosine signaling pathways including hnRNP sites in T cells. RDN2150 TFA can be used for psoriasis-related research .
loading...
    loading...
Cat. No.: HY-163028
CAS No.: 459789-75-4
Target:  

Tim3

Research Areas:  

Cancer

ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research .
loading...
    loading...
Cat. No.: HY-131911
CAS No.: 2488851-89-2
Purity:  99.00%
PROTAC IDO1 Degrader-1 is the first potent IDO1 (indoleamine 2,3-dioxygenase 1) degrader that hijacks IDO1 to Cereblon E3 ligase to introduce IDO1 into UPS and eventually achieve ubiquitination and degradation (DC50=2.84 μM). PROTAC IDO1 Degrader-1 moderately improves the tumor-killing activity of H ER2 CAR-T cells .
loading...
    loading...
Cat. No.: HY-P990870

Research Areas:  

Inflammation/Immunology

Anti-CD19 Antibody (4G7) is an anti-human CD19 IgG1 monoclonal antibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
loading...
    loading...
Cat. No.: HY-139678
CAS No.: 2839142-69-5
SC13 is an orally active, selective Flap structure-specific endonuclease 1 (FEN1) inhibitor and mu opioid receptor (MOR) activator. SC13 impairs DNA damage repair and induces apoptosis in cancer cells. SC13 activates cGAS-STING signaling, increases chemokine secretion, and promotes CAR-T cell infiltration at solid tumour sites. SC13 can be used for the research of solid tumours and pain .
loading...
    loading...
Cat. No.: HY-146231A
Purity:  99.88%
Target:  

PROTACs MAP4K

Research Areas:  

Inflammation/Immunology Cancer

SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies . SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-146231
CAS No.: 2636072-62-1
Target:  

PROTACs MAP4K

Research Areas:  

Inflammation/Immunology Cancer

SS47 is a hematopoietic progenitor kinase HPK1 PROTAC-class degrader and immune activator. SS47 promotes the proliferation of CD4+ and CD8+ T cells as well as IFN-γ secretion, and enhances the anti-tumor cytotoxicity and in vivo efficacy of BCMA CAR-T cells. SS47 also inhibits tumor growth in mouse models, and when combined with anti-PD-1 therapy, it improves the immune response of 4T1 tumor-bearing mice. SS47 can be used in breast cancer-related research .
loading...
    loading...
Cat. No.: HY-163168
CAS No.: 2412985-00-1
Synonyms: CFT-4531
Research Areas:  

Cancer

aTAG 4531 (CFT-4531) is a PROTAC-class degrader that induces the degradation of the MTH1/aTAG fusion protein by recruiting cereblon, with a DC50 of 0.28 nM in Jurkat cells. aTAG 4531 inhibits MTH1 enzymatic activity, with a Ki of 1.8 nM. aTAG 4531 rapidly, selectively and reversibly regulates SMART-CAR protein levels, CAR-mediated target cell killing and IL-2 release, and is applicable both in vitro and in vivo. aTAG 4531 can be used in studies of targeted protein degradation, target validation and CAR-T activity regulation .
loading...
    loading...
Cat. No.: HY-P99825
CAS No.: 2171034-70-9

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology Cancer

Relfovetmab is a monoclonal antibody and also serves as a single-chain variable fragment component for engineering chimeric antigen receptors (CAR) in modified CAR-T cells. Relfovetmab can be used in studies of cancer and immune disorders .
loading...
    loading...
Cat. No.: HY-160151
Research Areas:  

Cancer

TP1L is a potent and selective T-cell protein tyrosine phosphatase (TC-PTP) PROTAC degrader, with a DC50 value of 35.8 nM. TP1L elevates the phosphorylation level of TC-PTP substrates including pSTAT1 and pJAK1. TP1L selectively enhances IFN-γ signaling and increases MHC-I expression. TP1L activates TCR signaling through increases phosphorylation of LCK. TP1L enhances CAR-T cell mediated tumor killing efficacy through activation of the CAR-T cells. TP1L can be used for the study of cancer. (Pink: TC-PTP ligand: (HY-138964), Blue: E3 ligase CRBN Ligand (HY-A0003), Black: Linker: (HY-140002)) .
loading...
    loading...
Cat. No.: HY-155978
CAS No.: 2839429-51-3
RDN2150 is a ZAP-70 inhibitor with an IC50 of 14.6 nM, and it exhibits selectivity for Syk over other kinases. RDN2150 inhibits signal transduction and activation of T cells/CAR-T cells, reduces the phosphorylation level of Erk1/2, suppresses the induction of CD69 and IL-2, and downregulates phosphotyrosine signaling pathways including hnRNP sites in T cells. RDN2150 can be used for psoriasis-related research .
loading...
    loading...
Cat. No.: HY-157288
Research Areas:  

Metabolic Disease

(R)-Phe-A110/B319, a hapten, is a selective binder to tumor-associated antigens. (R)-Phe-A110/B319 has a 20-fold higher affinity towards the H1047R mutant of p110α in the p110α/p85α PI3K complex. (R)-Phe-A110/B319 can be used for the research of conditional chimeric antigen receptor T (CAR-T) cell activation and tumor targeting .
loading...
    loading...
Cat. No.: HY-156199
CAS No.: 3233-56-5
Target:  

Endogenous Metabolite

Research Areas:  

Inflammation/Immunology Cancer

o-Cresol sulfate is a biomarker related to CAR T cell-independent and dependent metabolic and inflammatory. o-Cresol sulfate can be used to predict patient response .
loading...
    loading...
Cat. No.: HY-174418
CAS No.: 2097522-37-5
NM600 is an alkylphosphocholine mimetic RPT agent. NM600 demonstrates an antitumor activity against a second GD2+ neuroblastoma xenograft model with SY5Y cells. NM600 can enhance suboptimal CAR T cell efficacy against solid tumors. NM600 can be studied in research for neuroblastoma .
loading...
    loading...
Cat. No.: HY-P11129
CAS No.: 289905-22-2
Target:  

Peptides

Research Areas:  

Cancer

MAGE-A4 (286-294) is a polypeptide derived from the 286th to 294th amino acids of the MAGE-A4 protein. MAGE-A4 (286-294) binds HLA-­A*02 with an affinity of 560.08 nM and an IC50 of 8.52 nM. MAGE-A4 (286-294) can be detected in various types of cancers (such as esophageal cancer, lung squamous cell carcinoma, bladder cancer). MAGE-A4 (286-294) can be used to produce CAR-T cells and to develop CAR-T cell therapy .
loading...
    loading...
Cat. No.: HY-185967
Target:  

mRNA

Research Areas:  

Others

CD19 mRNA (N1-methyl-pseudouridine) encodes the B cell surface antigen CD19, used in CAR-T cell research and immunological studies. CD19 plays two main functions in human B cells: as an aptamer protein, recruiting cytoplasmic signaling proteins to the cell membrane; and within the CD19/CD21 complex, lowering the activation threshold of B cell receptor signaling pathways.
loading...
    loading...
Cat. No.: HY-K2034

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology and is specifically optimized for human primary T cells. It enables efficient and targeted RNA delivery, improving transfection efficiency in difficult-to-transfect primary T cells. The kit is ideally suited for applications including CAR-T and TCR-T cell engineering, cancer immunology research, immune cell engineering, and in vitro T cell functional studies.

loading...
    loading...
Cat. No.: HY-185975
Target:  

mRNA

Research Areas:  

Others

Scarless CD19 CAR circular RNA (CVB3) is a circular RNA that uses CVB3 IRES to mediate scarless expression of the CD19 chimeric antigen receptor (CAR) for CAR-T cell research. This circular RNA features a scarless circularization design, eliminating the need for a linker or adapter sequence between the 5′ and 3′ ends, and achieving efficient circularization and expression without the need for optimized UTR elements.
loading...
    loading...